Loading…

Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, i...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2022-02, Vol.12 (2), p.27-8, Article 27
Main Authors: Dispenzieri, Angela, Krishnan, Amrita, Arendt, Bonnie, Blackwell, Beth, Wallace, Paul K., Dasari, Surendra, Vogl, Dan T., Efebera, Yvonne, Fei, Mingwei, Geller, Nancy, Giralt, Sergio, Hahn, Theresa, Howard, Alan, Kohlhagen, Mindy, Landau, Heather, Hari, Parameswaran, Pasquini, Marcelo C., Qazilbash, Muzaffar H., McCarthy, Philip, Shah, Nina, Vesole, David H., Stadtmauer, Edward, Murray, David
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673
cites cdi_FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673
container_end_page 8
container_issue 2
container_start_page 27
container_title Blood cancer journal (New York)
container_volume 12
creator Dispenzieri, Angela
Krishnan, Amrita
Arendt, Bonnie
Blackwell, Beth
Wallace, Paul K.
Dasari, Surendra
Vogl, Dan T.
Efebera, Yvonne
Fei, Mingwei
Geller, Nancy
Giralt, Sergio
Hahn, Theresa
Howard, Alan
Kohlhagen, Mindy
Landau, Heather
Hari, Parameswaran
Pasquini, Marcelo C.
Qazilbash, Muzaffar H.
McCarthy, Philip
Shah, Nina
Vesole, David H.
Stadtmauer, Edward
Murray, David
description Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.
doi_str_mv 10.1038/s41408-022-00624-6
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4550e3b5162c4ca0a41f3e9c97b698cb</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4550e3b5162c4ca0a41f3e9c97b698cb</doaj_id><sourcerecordid>2627131203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673</originalsourceid><addsrcrecordid>eNp9ks9uEzEQxlcIRKvSF-CALHEph6Xjv7t7QQoRgUhJi5Rwtrxeb-Jod73YDqIPwvviJKW0HPDFHs9vPs9YX5a9xvAeAy2vA8MMyhwIyQEEYbl4lp0TYCzntOTPH53PsssQdpAWF7jC1cvsjHLMOBT4PPu1VCHkM_sT1SZG49HoTWN1DKh1Hn2drZAaGnS7QnGrBhRiipRvUG_i1jUBqd4NG9Tvu2jHzqD-znSuV2hU0ZohiYzKR6vtIU6cG5KMQav1ZDm_maDorerQ1cflGk3XNwgKIOgaisX63avsRau6YC7v94vs2-zTevolX9x-nk8ni1xzBjEXgohSt5RyCrWgdVFCVdU1FtAUApjRpm4IBqUpMaXCjda8BYWLqsEgGlHQi2x-0m2c2snR2175O-mUlccL5zfyOEBnJOMcDK05FkQzrUAx3FJT6aqoRVXqOml9OGmN-7o3jU7ze9U9EX2aGexWbtwPWZYU8-rQzNW9gHff9yZE2dugTdepwbh9kESQkgImjCX07T_ozu39kL7qQBWYYgI0UeREae9C8KZ9aAaDPJhInkwkk4nk0URSpKI3j8d4KPljmQTQExBSatgY__ft_8j-Bgn1z9w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627131203</pqid></control><display><type>article</type><title>Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Dispenzieri, Angela ; Krishnan, Amrita ; Arendt, Bonnie ; Blackwell, Beth ; Wallace, Paul K. ; Dasari, Surendra ; Vogl, Dan T. ; Efebera, Yvonne ; Fei, Mingwei ; Geller, Nancy ; Giralt, Sergio ; Hahn, Theresa ; Howard, Alan ; Kohlhagen, Mindy ; Landau, Heather ; Hari, Parameswaran ; Pasquini, Marcelo C. ; Qazilbash, Muzaffar H. ; McCarthy, Philip ; Shah, Nina ; Vesole, David H. ; Stadtmauer, Edward ; Murray, David</creator><creatorcontrib>Dispenzieri, Angela ; Krishnan, Amrita ; Arendt, Bonnie ; Blackwell, Beth ; Wallace, Paul K. ; Dasari, Surendra ; Vogl, Dan T. ; Efebera, Yvonne ; Fei, Mingwei ; Geller, Nancy ; Giralt, Sergio ; Hahn, Theresa ; Howard, Alan ; Kohlhagen, Mindy ; Landau, Heather ; Hari, Parameswaran ; Pasquini, Marcelo C. ; Qazilbash, Muzaffar H. ; McCarthy, Philip ; Shah, Nina ; Vesole, David H. ; Stadtmauer, Edward ; Murray, David</creatorcontrib><description>Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.</description><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/s41408-022-00624-6</identifier><identifier>PMID: 35145071</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/31 ; 631/67/1990/804 ; 692/699/1541/1990/804 ; 82/58 ; Biomedical and Life Sciences ; Biomedicine ; Bone marrow ; Cancer ; Cancer Research ; Clinical trials ; Cytogenetics ; Diterpenes ; Enrollments ; Flow cytometry ; Flow Cytometry - methods ; Hematology ; Humans ; Hypotheses ; Laboratories ; Mass spectrometry ; Multiple myeloma ; Multiple Myeloma - diagnosis ; Multiple Myeloma - drug therapy ; Neoplasm, Residual - diagnosis ; Oncology ; Patients ; Prognosis ; Progression-Free Survival ; Scientific imaging ; Software ; Treatment Outcome</subject><ispartof>Blood cancer journal (New York), 2022-02, Vol.12 (2), p.27-8, Article 27</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673</citedby><cites>FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673</cites><orcidid>0000-0002-4163-8823 ; 0000-0003-2876-2886 ; 0000-0001-8780-9512 ; 0000-0003-1944-5053 ; 0000-0002-8800-297X ; 0000-0003-1720-335X ; 0000-0002-2935-2566 ; 0000-0002-3152-1189 ; 0000-0002-3835-8855</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2627131203/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2627131203?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35145071$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dispenzieri, Angela</creatorcontrib><creatorcontrib>Krishnan, Amrita</creatorcontrib><creatorcontrib>Arendt, Bonnie</creatorcontrib><creatorcontrib>Blackwell, Beth</creatorcontrib><creatorcontrib>Wallace, Paul K.</creatorcontrib><creatorcontrib>Dasari, Surendra</creatorcontrib><creatorcontrib>Vogl, Dan T.</creatorcontrib><creatorcontrib>Efebera, Yvonne</creatorcontrib><creatorcontrib>Fei, Mingwei</creatorcontrib><creatorcontrib>Geller, Nancy</creatorcontrib><creatorcontrib>Giralt, Sergio</creatorcontrib><creatorcontrib>Hahn, Theresa</creatorcontrib><creatorcontrib>Howard, Alan</creatorcontrib><creatorcontrib>Kohlhagen, Mindy</creatorcontrib><creatorcontrib>Landau, Heather</creatorcontrib><creatorcontrib>Hari, Parameswaran</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Qazilbash, Muzaffar H.</creatorcontrib><creatorcontrib>McCarthy, Philip</creatorcontrib><creatorcontrib>Shah, Nina</creatorcontrib><creatorcontrib>Vesole, David H.</creatorcontrib><creatorcontrib>Stadtmauer, Edward</creatorcontrib><creatorcontrib>Murray, David</creatorcontrib><title>Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer J</addtitle><addtitle>Blood Cancer J</addtitle><description>Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.</description><subject>13/31</subject><subject>631/67/1990/804</subject><subject>692/699/1541/1990/804</subject><subject>82/58</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone marrow</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Clinical trials</subject><subject>Cytogenetics</subject><subject>Diterpenes</subject><subject>Enrollments</subject><subject>Flow cytometry</subject><subject>Flow Cytometry - methods</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Laboratories</subject><subject>Mass spectrometry</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Scientific imaging</subject><subject>Software</subject><subject>Treatment Outcome</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks9uEzEQxlcIRKvSF-CALHEph6Xjv7t7QQoRgUhJi5Rwtrxeb-Jod73YDqIPwvviJKW0HPDFHs9vPs9YX5a9xvAeAy2vA8MMyhwIyQEEYbl4lp0TYCzntOTPH53PsssQdpAWF7jC1cvsjHLMOBT4PPu1VCHkM_sT1SZG49HoTWN1DKh1Hn2drZAaGnS7QnGrBhRiipRvUG_i1jUBqd4NG9Tvu2jHzqD-znSuV2hU0ZohiYzKR6vtIU6cG5KMQav1ZDm_maDorerQ1cflGk3XNwgKIOgaisX63avsRau6YC7v94vs2-zTevolX9x-nk8ni1xzBjEXgohSt5RyCrWgdVFCVdU1FtAUApjRpm4IBqUpMaXCjda8BYWLqsEgGlHQi2x-0m2c2snR2175O-mUlccL5zfyOEBnJOMcDK05FkQzrUAx3FJT6aqoRVXqOml9OGmN-7o3jU7ze9U9EX2aGexWbtwPWZYU8-rQzNW9gHff9yZE2dugTdepwbh9kESQkgImjCX07T_ozu39kL7qQBWYYgI0UeREae9C8KZ9aAaDPJhInkwkk4nk0URSpKI3j8d4KPljmQTQExBSatgY__ft_8j-Bgn1z9w</recordid><startdate>20220210</startdate><enddate>20220210</enddate><creator>Dispenzieri, Angela</creator><creator>Krishnan, Amrita</creator><creator>Arendt, Bonnie</creator><creator>Blackwell, Beth</creator><creator>Wallace, Paul K.</creator><creator>Dasari, Surendra</creator><creator>Vogl, Dan T.</creator><creator>Efebera, Yvonne</creator><creator>Fei, Mingwei</creator><creator>Geller, Nancy</creator><creator>Giralt, Sergio</creator><creator>Hahn, Theresa</creator><creator>Howard, Alan</creator><creator>Kohlhagen, Mindy</creator><creator>Landau, Heather</creator><creator>Hari, Parameswaran</creator><creator>Pasquini, Marcelo C.</creator><creator>Qazilbash, Muzaffar H.</creator><creator>McCarthy, Philip</creator><creator>Shah, Nina</creator><creator>Vesole, David H.</creator><creator>Stadtmauer, Edward</creator><creator>Murray, David</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4163-8823</orcidid><orcidid>https://orcid.org/0000-0003-2876-2886</orcidid><orcidid>https://orcid.org/0000-0001-8780-9512</orcidid><orcidid>https://orcid.org/0000-0003-1944-5053</orcidid><orcidid>https://orcid.org/0000-0002-8800-297X</orcidid><orcidid>https://orcid.org/0000-0003-1720-335X</orcidid><orcidid>https://orcid.org/0000-0002-2935-2566</orcidid><orcidid>https://orcid.org/0000-0002-3152-1189</orcidid><orcidid>https://orcid.org/0000-0002-3835-8855</orcidid></search><sort><creationdate>20220210</creationdate><title>Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)</title><author>Dispenzieri, Angela ; Krishnan, Amrita ; Arendt, Bonnie ; Blackwell, Beth ; Wallace, Paul K. ; Dasari, Surendra ; Vogl, Dan T. ; Efebera, Yvonne ; Fei, Mingwei ; Geller, Nancy ; Giralt, Sergio ; Hahn, Theresa ; Howard, Alan ; Kohlhagen, Mindy ; Landau, Heather ; Hari, Parameswaran ; Pasquini, Marcelo C. ; Qazilbash, Muzaffar H. ; McCarthy, Philip ; Shah, Nina ; Vesole, David H. ; Stadtmauer, Edward ; Murray, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>13/31</topic><topic>631/67/1990/804</topic><topic>692/699/1541/1990/804</topic><topic>82/58</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone marrow</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Clinical trials</topic><topic>Cytogenetics</topic><topic>Diterpenes</topic><topic>Enrollments</topic><topic>Flow cytometry</topic><topic>Flow Cytometry - methods</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Laboratories</topic><topic>Mass spectrometry</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Scientific imaging</topic><topic>Software</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dispenzieri, Angela</creatorcontrib><creatorcontrib>Krishnan, Amrita</creatorcontrib><creatorcontrib>Arendt, Bonnie</creatorcontrib><creatorcontrib>Blackwell, Beth</creatorcontrib><creatorcontrib>Wallace, Paul K.</creatorcontrib><creatorcontrib>Dasari, Surendra</creatorcontrib><creatorcontrib>Vogl, Dan T.</creatorcontrib><creatorcontrib>Efebera, Yvonne</creatorcontrib><creatorcontrib>Fei, Mingwei</creatorcontrib><creatorcontrib>Geller, Nancy</creatorcontrib><creatorcontrib>Giralt, Sergio</creatorcontrib><creatorcontrib>Hahn, Theresa</creatorcontrib><creatorcontrib>Howard, Alan</creatorcontrib><creatorcontrib>Kohlhagen, Mindy</creatorcontrib><creatorcontrib>Landau, Heather</creatorcontrib><creatorcontrib>Hari, Parameswaran</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Qazilbash, Muzaffar H.</creatorcontrib><creatorcontrib>McCarthy, Philip</creatorcontrib><creatorcontrib>Shah, Nina</creatorcontrib><creatorcontrib>Vesole, David H.</creatorcontrib><creatorcontrib>Stadtmauer, Edward</creatorcontrib><creatorcontrib>Murray, David</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dispenzieri, Angela</au><au>Krishnan, Amrita</au><au>Arendt, Bonnie</au><au>Blackwell, Beth</au><au>Wallace, Paul K.</au><au>Dasari, Surendra</au><au>Vogl, Dan T.</au><au>Efebera, Yvonne</au><au>Fei, Mingwei</au><au>Geller, Nancy</au><au>Giralt, Sergio</au><au>Hahn, Theresa</au><au>Howard, Alan</au><au>Kohlhagen, Mindy</au><au>Landau, Heather</au><au>Hari, Parameswaran</au><au>Pasquini, Marcelo C.</au><au>Qazilbash, Muzaffar H.</au><au>McCarthy, Philip</au><au>Shah, Nina</au><au>Vesole, David H.</au><au>Stadtmauer, Edward</au><au>Murray, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer J</stitle><addtitle>Blood Cancer J</addtitle><date>2022-02-10</date><risdate>2022</risdate><volume>12</volume><issue>2</issue><spage>27</spage><epage>8</epage><pages>27-8</pages><artnum>27</artnum><issn>2044-5385</issn><eissn>2044-5385</eissn><abstract>Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35145071</pmid><doi>10.1038/s41408-022-00624-6</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4163-8823</orcidid><orcidid>https://orcid.org/0000-0003-2876-2886</orcidid><orcidid>https://orcid.org/0000-0001-8780-9512</orcidid><orcidid>https://orcid.org/0000-0003-1944-5053</orcidid><orcidid>https://orcid.org/0000-0002-8800-297X</orcidid><orcidid>https://orcid.org/0000-0003-1720-335X</orcidid><orcidid>https://orcid.org/0000-0002-2935-2566</orcidid><orcidid>https://orcid.org/0000-0002-3152-1189</orcidid><orcidid>https://orcid.org/0000-0002-3835-8855</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2044-5385
ispartof Blood cancer journal (New York), 2022-02, Vol.12 (2), p.27-8, Article 27
issn 2044-5385
2044-5385
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4550e3b5162c4ca0a41f3e9c97b698cb
source Publicly Available Content Database; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 13/31
631/67/1990/804
692/699/1541/1990/804
82/58
Biomedical and Life Sciences
Biomedicine
Bone marrow
Cancer
Cancer Research
Clinical trials
Cytogenetics
Diterpenes
Enrollments
Flow cytometry
Flow Cytometry - methods
Hematology
Humans
Hypotheses
Laboratories
Mass spectrometry
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Neoplasm, Residual - diagnosis
Oncology
Patients
Prognosis
Progression-Free Survival
Scientific imaging
Software
Treatment Outcome
title Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mass-Fix%20better%20predicts%20for%20PFS%20and%20OS%20than%20standard%20methods%20among%20multiple%20myeloma%20patients%20participating%20on%20the%20STAMINA%20trial%20(BMT%20CTN%200702%20/07LT)&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Dispenzieri,%20Angela&rft.date=2022-02-10&rft.volume=12&rft.issue=2&rft.spage=27&rft.epage=8&rft.pages=27-8&rft.artnum=27&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/s41408-022-00624-6&rft_dat=%3Cproquest_doaj_%3E2627131203%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-66268cf33530b63b78099bb160d7604ecebd210ac32e8a1dcc5f0a179d106d673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2627131203&rft_id=info:pmid/35145071&rfr_iscdi=true